Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas

✍ Scribed by McCowage, Geoffrey B.; Friedman, Henry S.; Moghrabi, Albert; Kerby, Tracy; Ferrell, Lee; Stewart, Elizabeth; Duncan-Brown, Margaret; Fuchs, Herbert E.; Tien, Robert; McLendon, Roger E.; Meier, Lisa; Kurtzberg, Joanne; Ashley, David; Colvin, O. Michael; Longee, Darryl C.

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 225 KB
• Volume: 30
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199802)30:2<75::aid-mpo1>3.0.co;2-x

✦ Synopsis

Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was given at a dose of 2 g/m 2 daily for 2 days at 4-week intervals. Toxicity consisted of grade IV neutropenia and thrombocytopenia in 95% and 48% of cycles, respectively. There were no cyclophos-phamide-related cardiac, pulmonary, or urothelial toxicities observed. Four of 10 patients with newly diagnosed disease demonstrated responses (three complete and one partial responses; one CR was only of 2 months duration). None of the seven patients with recurrent tumors demonstrated a response. We conclude that high-dose cyclophosphamide warrants further evaluation in children with newly diagnosed malignant glioma.